Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (FCT)/ Ministério da Ciência, Tecnologia e Ensino Superior (UID/BIM/50005/2019)
Text and Data Mining valid from 2020-03-06
Received: 18 July 2019
Accepted: 25 February 2020
First Online: 6 March 2020
Ethics approval and consent to participate
: All THAOS study sites received ethical or institutional review board approval prior to subject enrolment, and each subject provided written informed consent. The current study protocol was approved by the Portuguese National Data Protection Committee (file number 9309/2016).
: Not applicable.
: MI is Outcomes & Evidence Senior Manager, full-time employee of Pfizer and hold stock and/or stock options. TC received financial support from Alnylam, Ionis, and Pfizer to attend scientific meetings and personal fees from Alnylam and Pfizer to provide scientific lectures. IC acknowledges financial support as primary investigator of clinical studies from FoldRx Pharmaceuticals/Pfizer Inc., Alnylam Pharmaceuticals and Ionis Pharmaceuticals. She also received research support from Pfizer and serves on the THAOS scientific advisory board, financially supported from Pfizer. IC also participates in medical advisory boards promoted by Alnylam and Pfizer. LF, MC and JC report no disclosures relevant to the manuscript.